PROCEPT BioRobotics (NASDAQ:PRCT) Issues Earnings Results, Beats Expectations By $0.03 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings results on Tuesday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03, Zacks reports. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. PROCEPT BioRobotics updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

PROCEPT BioRobotics Trading Up 1.5%

NASDAQ:PRCT traded up $0.51 on Tuesday, reaching $35.02. The company’s stock had a trading volume of 2,493,975 shares, compared to its average volume of 1,041,929. PROCEPT BioRobotics has a 12-month low of $32.11 and a 12-month high of $103.81. The company has a quick ratio of 7.86, a current ratio of 9.21 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -22.59 and a beta of 0.99. The stock has a 50 day moving average price of $36.66 and a 200 day moving average price of $48.17.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PRCT shares. Piper Sandler cut their price target on shares of PROCEPT BioRobotics from $80.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Wells Fargo & Company cut their price objective on PROCEPT BioRobotics from $75.00 to $58.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Oppenheimer upgraded PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research note on Tuesday, September 2nd. Morgan Stanley cut their price objective on PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $67.50.

Institutional Investors Weigh In On PROCEPT BioRobotics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of PROCEPT BioRobotics by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after buying an additional 13,767 shares during the period. Advisory Services Network LLC boosted its position in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after buying an additional 250 shares during the period. Militia Capital Partners LP boosted its position in shares of PROCEPT BioRobotics by 57.1% during the second quarter. Militia Capital Partners LP now owns 22,000 shares of the company’s stock worth $1,267,000 after buying an additional 8,000 shares during the period. Brevan Howard Capital Management LP purchased a new position in shares of PROCEPT BioRobotics during the second quarter worth $407,000. Finally, California State Teachers Retirement System boosted its position in shares of PROCEPT BioRobotics by 1.4% during the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock worth $2,848,000 after buying an additional 693 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).